Global Longlife Hospital And Research Ltd vs Kmc Speciality Hospitals India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.57 as of 23 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 25.7 on March 2023 to 0 on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of KMC Speciality Hospitals (India) Ltd changed from 28 on March 2021 to 27.4 on March 2026 . This represents a CAGR of -0.36% over 6 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 47.02 crore on March 2023 to ₹ 14.34 crore on March 2026 . This represents a CAGR of -25.69% over 4 yearsThe Market Cap of KMC Speciality Hospitals (India) Ltd changed from ₹ 355.56 crore on March 2021 to ₹ 1284 crore on March 2026 . This represents a CAGR of 23.87% over 6 years The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 93.58 crore as compare to the Mar '26 revenue of ₹ 84.16 crore. This represent the growth of 11.19% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 30.29 crore as compare to the Mar '26 ebitda of ₹ 27.78 crore. This represent the growth of 9.04% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of KMC Speciality Hospitals (India) Ltd changed from ₹ 5.51 crore to ₹ 16.57 crore over 9 quarters. This represents a CAGR of 63.12% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of KMC Speciality Hospitals (India) Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution that offer to every human being, high quality healthcare at affordable prices in Ahmedabad. Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About KMC Speciality Hospitals (India) Ltd

KMC Speciality Hospitals (India) Limited was originally incorporated as 'Advanced Medical Care Private Limited' on December 31, 1982 and was converted into a Public Limited Company on July 15, 1988.
The name of the Company was changed to 'Seahorse Hospitals Limited' on March 21, 1995 and to its current name 'KMC Speciality Hospitals (India) Limited' with effect from October 24, 2008. The Company is a part of the KMC Group of Hospitals based at Tiruchirappalli.
The Company is a super speciality hospital based in Trichy, belonging to the Kauvery Hospitals Group.
The Company is primarily engaged in the business of rendering medical and healthcare services.
It provide quality healthcare to patients in key specialty areas such as Neurosurgery, Cardiovascular & thoracic surgery, Orthopedics, Plastic and Reconstructive Surgery, Gynecology, Neonatology and Nephrology (including renal transplants).

FAQs for the comparison of Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or KMC Speciality Hospitals (India) Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of KMC Speciality Hospitals (India) Ltd is 2,351 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd?

As of October 25, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.57. On the other hand, KMC Speciality Hospitals (India) Ltd stock price is INR ₹144.2.

How do dividend payouts of Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and KMC Speciality Hospitals (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.